



NOCA

National Ovarian
Cancer Audit

NOCA, Clinical Effectiveness Unit

Royal College of Surgeons of England
38-43 Lincoln's Inn Fields
London WC2A 3PE

E: OvarianCancerAudit@rcseng.ac.uk


T: 020 7869 6606

 [NOCA_NATCAN](https://twitter.com/NOCA_NATCAN)

NOCA Newsletter, Summer 2023

Want to hear more?

The NOCA is part of the National Cancer Audit Collaborating Centre (NATCAN). If you want to find out more about NATCAN visit our [new website](#). If you would like to receive regular updates send us an email NATCAN@rcseng.ac.uk



1. Announcing the launch of NOCA!

We are excited to announce the launch of the new National Ovarian Cancer Audit (NOCA) as part of NATCAN (National Audit Collaborating Centre), hosted by the Clinical Effectiveness Unit at the Royal College of Surgeons of England since October 2022. Commissioned by the Healthcare Quality Improvement Partnership on behalf of NHS England and the Welsh Government, NATCAN will be a new national centre of excellence in cancer audit. Building on the previous work of the Ovarian Cancer Audit Feasibility Pilot, the audit aims to support NHS services to increase the consistency of access to treatments and help guide quality improvement initiatives and stimulate quality improvements leading to better outcomes for patients.

2. Introducing our clinical leads

We are delighted to have two experienced Clinical Leads as part of our Project Team:

Prof Sudha Sundar - Gynaecological Oncologist and Professor of Gynaecological Cancer, University of Birmingham: "I am absolutely delighted that we will be building on the important learnings from the National Ovarian Cancer Feasibility Audit. This will help patients, carers, charities, and the clinical community understand how we can best drive standards of ovarian cancer care forwards across both surgery and chemotherapy."

Dr Agnieszka Michael - Medical Oncologist and Associate Professor in Medical Oncology, University of Surrey: "I believe that the National Ovarian Cancer Audit has the potential to make a very big impact on the outcomes of treatment across the country. Ovarian cancer is still known as the "silent killer", and it is essential that we deliver the highest quality care that is equally effective and accessible in all cancer centres, so every patient who is diagnosed with this condition has access to the best treatment available."

3. Data

A guiding principle for NOCA is to keep the burden of data collection to a minimum by using existing national datasets (e.g., Cancer Registration Data and Hospital Episode Statistics) rather than collecting bespoke data. For English patients the NOCA has access to the Gold Standard dataset and Rapid Cancer Registration Dataset (RCRD). During the first year, we will explore how to use these datasets to define robust indicators that can support NOCA's quality improvement initiatives and decision making by cancer services.

